Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BLTE
HoldHot AirBelite Bio, Inc · Healthcare · United States · $6.1B · Avg Vol: $38M/d
COMPANY DESCRIPTION
Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for retinal diseases. The company targets serious eye diseases with high unmet medical needs, such as Stargardt disease and dry Age-related Macular Degeneration (AMD), leveraging its proprietary drug candidates. Belite Bio is a specialized ophthalmology biotech firm, dedicated to advancing treatments for degenerative eye conditions.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 258.5M | — |
| EPS | — | -0.63 | -1.19 | -1.18 | -2.31 | — | -2.74 | -2.94 | 1.92 | — |
| Shares | — | 24.9M | 29.1M | 31.8M | 39.3M | +58.0% | 40.3M | — | — | — |
| Debt | — | 0.9M | 0.9M | 0.5M | 0.4M | -20.9% | — | — | — | — |
| Equity | — | 41.5M | 90.4M | 145.8M | 770.5M | 164.8% | — | — | — | — |
| Op CF | — | -11.5M | -29.8M | -29.2M | -37.0M | — | -37.0M | — | — | — |
| Inv CF | — | -0.4M | -63.0K | -110.6M | -305.1M | — | — | — | — | — |
| Fin CF | — | 37.0M | 76.0M | 83.6M | 663.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BLTE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BLTE | Belite Bio, Inc(you) | $6.1B | 42 | Hold |
| PTGX | Protagonist Therapeutics, Inc. | $9.3B | 44 | Hold |
| PTCT | PTC Therapeutics, Inc. | $5.8B | 32 | Sell |
| TVTX | Travere Therapeutics, Inc. | $6.2B | 54 | Hold |
| ELVN | Enliven Therapeutics, Inc. | $4.2B | 37 | Hold |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.9B | 30 | Sell |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.4B | 33 | Sell |
| IOVA | Iovance Biotherapeutics, Inc. | $3.6B | 39 | Hold |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.1B | 44 | Hold |
| ORKA | Oruka Therapeutics, Inc. | $6.0B | 27 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.3%